Andrew Mcmurtrie Mason
University of Hertfordshire
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrew Mcmurtrie Mason.
Nucleosides, Nucleotides & Nucleic Acids | 1999
Richard Storer; Claire J. Ashton; Anthony D. Baxter; Michael Menteith Hann; Clara L.P. Marr; Andrew Mcmurtrie Mason; Chi-Leung Mo; Peter L. Myers; Stewart A. Noble; Charles R. Penn; Niall Galbraith Weir; Jacqueline M. Woods; Paul L. Coe
A novel fluoropyrazole ribonucleoside has been shown to have significant anti-influenza activity in vitro. The compound is compared and contrasted with the structurally-related compound ribavirin in attempts to identify factors having significant bearing on the mode of action of both compounds.
Antimicrobial Agents and Chemotherapy | 2004
Simon J. F. Macdonald; Keith Geoffrey Watson; Rachel Cameron; David K. Chalmers; Derek Anthony Demaine; Rob J. Fenton; David Gower; J. Nicole Hamblin; Stephanie Hamilton; Graham J. Hart; Graham G. A. Inglis; Betty Jin; Haydn Terence Jones; Darryl Mcconnell; Andrew Mcmurtrie Mason; Van T. T. Nguyen; Ian J. Owens; Nigel R. Parry; Phillip A. Reece; Stephen E. Shanahan; Donna L. Smith; Wen-Yang Wu; Simon P. Tucker
ABSTRACT Dimeric derivatives (compounds 7 to 9) of the influenza virus neuraminidase inhibitor zanamivir (compound 2), which have linking groups of 14 to 18 atoms in length, are approximately 100-fold more potent inhibitors of influenza virus replication in vitro and in vivo than zanamivir. The observed optimum linker length of 18 to 22 Å, together with observations that the dimers cause aggregation of isolated neuraminidase tetramers and whole virus, indicate that the dimers benefit from multivalent binding via intertetramer and intervirion linkages. The outstanding long-lasting protective activities shown by compounds 8 and 9 in mouse influenza infectivity experiments and the extremely long residence times observed in the lungs of rats suggest that a single low dose of a dimer would provide effective treatment and prophylaxis for influenza virus infections.
Journal of Medicinal Chemistry | 2006
Alan David Borthwick; John Liddle; Dave E. Davies; Anne M. Exall; Christopher Hamlett; Deirdre Mary Bernadette Hickey; Andrew Mcmurtrie Mason; Ian Edward David Smith; Fabrizio Nerozzi; Simon Peace; Derek Pollard; Steve L. Sollis; Michael J. Allen; Patrick M. Woollard; Mark Pullen; Timothy D. Westfall; Dinesh J. Stanislaus
Journal of Medicinal Chemistry | 2002
Alan D. Borthwick; Andrew James Crame; Peter Ertl; Anne M. Exall; Terry M. Haley; Graham J. Hart; Andrew Mcmurtrie Mason; Andrew M. K. Pennell; Onkar M. P. Singh; Gordon G. Weingarten; James Michael Woolven
Journal of Medicinal Chemistry | 2000
Alan D. Borthwick; S. Jane Angier; Andrew James Crame; Anne M. Exall; Terry M. Haley; Graham J. Hart; Andrew Mcmurtrie Mason; Andrew M. K. Pennell; Gordon G. Weingarten
Archive | 2004
Mathew Campbell; Richard Jonathan Hatley; Jag Paul Heer; Andrew Mcmurtrie Mason; Neville Hubert Nicholson; Ivan Leo Pinto; Shahzad Sharooq Rahman; Ian Edward David Smith
Archive | 2004
Mathew Campbell; Richard Jonathan Hatley; Jag Paul Heer; Andrew Mcmurtrie Mason; Ivan Leo Pinto; Shahzad Sharooq Rahman; Ian Edward David Smith
Archive | 2001
Gerard Martin Paul Giblin; Haydn Terence Jones; Andrew Mcmurtrie Mason; Neil Derek Miller; Susan Roomans; Stephen E. Shanahan; Ann Louise Walker
Archive | 2002
Alan David Borthwick; Richard Jonathan Hatley; Deirdre Mary Bernadette Hickey; John Liddle; David G. Livermore; Andrew Mcmurtrie Mason; Neil Derek Miller; Fabrizio Nerozzi; Steven Leslie Sollis; Anna Katrin Szardenings; Paul G. Wyatt
Archive | 2001
Wen-Yang Wu; Michael Dennis Dowle; Betty Jin; Simon J. F. Macdonald; Andrew Mcmurtrie Mason; Darryl Mcconnell; Keith Geoffrey Watson